Transcept Pharmaceuticals, Inc. announced today an update on its plans to seek U.S. Food and Drug Administration approval of Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.  Transcept met with the FDA on January 20, 2010 to discuss the Complete Response Letter dated October 28, 2009, and received the …
Controlled release prescription sleep medication, indicated for the treatment of insomnia. From Sanofi-Synthelabo.
Health Canada has announced label updates for several medications used in the short-term treatment of insomnia. The prescription sleep aids subject to the label revision include: * Dalmane, Som Pam (flurazepam) * Mogadon, Nitrazadon (nitrazepam) * [...]
OTTAWA, ONTARIO–(Marketwire - Oct. 7, 2009) - Health Canada is informing consumers and health professionals of recent changes to the labelling information of prescription sleep aid medications used in the short-term treatment of insomnia. Sleep aid drugs are used for short-term treatment of insomnia characterized by difficulty in falling asleep, or waking up often during the night or in the …
Ambien is used for the short-term treatment of insomnia. The key here is “short term.” Symptoms that last longer than two weeks should be addressed by a physician to determine whether an undiagnosed medical problem exists. In any event, Ambien works quickly and should be taken just before bedtime. Because there is no way of anticipating what effects the sleep aid will have, this, as well as all …
